Scribe Therapeutics Inc. <SCTX.O>: H.C. Wainwright initiates coverage with buy rating and target price $60
SCTX•Related News
Lilly to acquire Merida Biosciences in deal worth up to USD 2.88 billion
LLY•
PayPal <PYPL.O>: Truist Securities cuts target price to $53 from $62
PYPL•
Radware COO Gabriel Malka sells 6,500 shares for $195,000
RDWR•
Northern Dynasty Minerals says director Wayne Kirk steps down from board
NAK•
Clough Global Equity Fund pays $0.07 per share monthly distribution
GLQ•